therapeutics

Summary

Summary: Procedures concerned with the remedial treatment or prevention of diseases.

Top Publications

  1. doi Developing microRNA therapeutics
    Eva van Rooij
    miRagen Therapeutics, Inc, Boulder, CO 80301, USA
    Circ Res 110:496-507. 2012
  2. doi Promises, facts and challenges for carbon nanotubes in imaging and therapeutics
    K Kostarelos
    Nanomedicine Laboratory, Centre for Drug Delivery Research, The School of Pharmacy, University of London, London WC1N 1AX, UK
    Nat Nanotechnol 4:627-33. 2009
  3. pmc p38(MAPK): stress responses from molecular mechanisms to therapeutics
    Lydia R Coulthard
    NIHR Leeds Musculoskeletal Biomedical Research Unit, St James s University Hospital, Leeds, LS9 7TF, UK
    Trends Mol Med 15:369-79. 2009
  4. doi Bringing next-generation therapeutics to the clinic through synthetic biology
    Lukasz J Bugaj
    Department of Bioengineering, University of California, Berkeley, Berkeley, CA 94720, USA
    Curr Opin Chem Biol 16:355-61. 2012
  5. pmc The importance of chemistry in creating well-defined nanoscopic embedded therapeutics: devices capable of the dual functions of imaging and therapy
    Andreas M Nyström
    The Swedish Medical Nanoscience Center, Department of Neuroscience, Karolinska Institutet, SE 17177 Stockholm, Sweden
    Acc Chem Res 44:969-78. 2011
  6. ncbi Discovery and development of anticancer agents from marine sponges: perspectives based on a chemistry-experimental therapeutics collaborative program
    Frederick A Valeriote
    Josephine Ford Cancer Center, Division of Hematology and Oncology, Department of Internal Medicine, Henry Ford Health System, Detroit, MI 48202, USA
    J Exp Ther Oncol 10:119-34. 2012
  7. doi Sirtuins in dermatology: applications for future research and therapeutics
    Melissa Serravallo
    Department of Dermatology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    Arch Dermatol Res 305:269-82. 2013
  8. pmc Mitochondrial energetics and therapeutics
    Douglas C Wallace
    Center for Molecular and Mitochondrial Medicine and Genetics and Departments of Biological Chemistry, Ecology and Evolutionary Biology, and Pediatrics, University of California at Irvine, Irvine, California 92697 3940, USA
    Annu Rev Pathol 5:297-348. 2010
  9. pmc Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics
    Biana Godin
    Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, Texas 77030, USA
    Acc Chem Res 44:979-89. 2011
  10. ncbi Developmental therapeutics program at the NCI: molecular target and drug discovery process
    M Monga
    Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Executive Plaza North, Rockville, MD 20852, USA
    Leukemia 16:520-6. 2002

Detail Information

Publications465 found, 100 shown here

  1. doi Developing microRNA therapeutics
    Eva van Rooij
    miRagen Therapeutics, Inc, Boulder, CO 80301, USA
    Circ Res 110:496-507. 2012
    ....
  2. doi Promises, facts and challenges for carbon nanotubes in imaging and therapeutics
    K Kostarelos
    Nanomedicine Laboratory, Centre for Drug Delivery Research, The School of Pharmacy, University of London, London WC1N 1AX, UK
    Nat Nanotechnol 4:627-33. 2009
    ..We address common questions regarding the use of carbon nanotubes in disease imaging and therapy, and highlight the opportunities and challenges ahead...
  3. pmc p38(MAPK): stress responses from molecular mechanisms to therapeutics
    Lydia R Coulthard
    NIHR Leeds Musculoskeletal Biomedical Research Unit, St James s University Hospital, Leeds, LS9 7TF, UK
    Trends Mol Med 15:369-79. 2009
    ..We summarize how this pathway has been exploited for the development of therapeutics and discuss the potential obstacles of targeting this promiscuous protein kinase pathway for the treatment of ..
  4. doi Bringing next-generation therapeutics to the clinic through synthetic biology
    Lukasz J Bugaj
    Department of Bioengineering, University of California, Berkeley, Berkeley, CA 94720, USA
    Curr Opin Chem Biol 16:355-61. 2012
    ..Here we review engineered circuits with clinical potential and discuss their design, implementation, and validation...
  5. pmc The importance of chemistry in creating well-defined nanoscopic embedded therapeutics: devices capable of the dual functions of imaging and therapy
    Andreas M Nyström
    The Swedish Medical Nanoscience Center, Department of Neuroscience, Karolinska Institutet, SE 17177 Stockholm, Sweden
    Acc Chem Res 44:969-78. 2011
    ....
  6. ncbi Discovery and development of anticancer agents from marine sponges: perspectives based on a chemistry-experimental therapeutics collaborative program
    Frederick A Valeriote
    Josephine Ford Cancer Center, Division of Hematology and Oncology, Department of Internal Medicine, Henry Ford Health System, Detroit, MI 48202, USA
    J Exp Ther Oncol 10:119-34. 2012
    ..Phillip Crews at the University of California Santa Cruz and the experimental therapeutics laboratory of Dr. Fred Valeriote at the Henry Ford Hospital in Detroit...
  7. doi Sirtuins in dermatology: applications for future research and therapeutics
    Melissa Serravallo
    Department of Dermatology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    Arch Dermatol Res 305:269-82. 2013
    ..This review highlights sirtuin-related cellular pathways, therapeutics and pharmacological targets in atopic dermatitis, bullous dermatoses, collagen vascular disorders, psoriasis, ..
  8. pmc Mitochondrial energetics and therapeutics
    Douglas C Wallace
    Center for Molecular and Mitochondrial Medicine and Genetics and Departments of Biological Chemistry, Ecology and Evolutionary Biology, and Pediatrics, University of California at Irvine, Irvine, California 92697 3940, USA
    Annu Rev Pathol 5:297-348. 2010
    ..glycolytic metabolism to fatty acid and ketone oxidative metabolism may modulate metabolism, signal transduction pathways, and the epigenome gives us an appreciation of the ketogenic diet and the potential for bioenergetic therapeutics.
  9. pmc Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics
    Biana Godin
    Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, Texas 77030, USA
    Acc Chem Res 44:979-89. 2011
    ..a variety of novel properties emerge, which enable the design of new and improved imaging contrast agents and therapeutics. For example, the loading of the MRI Gd-based contrast agents onto hemispherical and discoidal S1MPs ..
  10. ncbi Developmental therapeutics program at the NCI: molecular target and drug discovery process
    M Monga
    Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Executive Plaza North, Rockville, MD 20852, USA
    Leukemia 16:520-6. 2002
    As the drug discovery and developmental arm of the National Cancer Institute (NCI), the Developmental Therapeutics Program (DTP) plans, conducts and facilitates development of therapeutic agents for cancer and AIDS...
  11. ncbi Translating basic cancer research into new cancer therapeutics
    Paul Workman
    Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, SM2 5NG, UK
    Trends Mol Med 8:S1-9. 2002
  12. ncbi The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the concept
    P J Thornalley
    Department of Biological Sciences, University of Essex, Central Campus, Wivenhoe Park, Colchester, Essex CO4 3SQ, U K
    Biochem Soc Trans 31:1341-2. 2003
    ..Improved understanding of the balance between glycation and the enzymatic anti-glycation defence will advance disease diagnosis and therapy...
  13. ncbi Macromolecular therapeutics: emerging strategies for drug discovery in the postgenome era
    R L Juliano
    Department of Pharmacology, School of Medicine and Program in Macromolecular Therapeutics, University of North Carolina, Chapel Hill 27599, USA
    Mol Interv 1:40-53. 2001
    ..Thus, the therapeutic use of macromolecules, including oligonucleotides, peptides, and proteins, may be an idea whose time has come...
  14. pmc Virtual patients and problem-based learning in advanced therapeutics
    Neal Benedict
    University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA
    Am J Pharm Educ 74:143. 2010
    To enhance student learning of a complex therapeutic concept through the incorporation of 2 case-based, active-learning strategies with lecture in a required advanced therapeutics course.
  15. ncbi Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy
    Karl Kieburtz
    Neurology Department, University of Rochester Medical Center, Rochester, New York 14620, USA
    Mt Sinai J Med 74:7-14. 2007
    ..We use the term "translational experimental therapeutics" to describe the pathway between the discovery of a basic disease mechanism or novel therapeutic approach and ..
  16. doi Oligosaccharides from land plants and algae: production and applications in therapeutics and biotechnology
    Josiane Courtois
    Laboratoire des Polysaccharides Microbiens et Végétaux, IUT GB, Universite de Picardie Jules Verne, Avenue des Facultés le Bailly, Amiens, France
    Curr Opin Microbiol 12:261-73. 2009
    ..So, to be adapted to the receptor, the oligosaccharides have to present specific groups to the receptor, there, the polymerization degree of oligosaccharides as well as the flexibility of the glycosidic linkages has to be considered...
  17. ncbi The in-flow capture of superparamagnetic nanoparticles for targeting therapeutics
    Nicholas J Darton
    Department of Chemical Engineering, University of Cambridge, Cambridge, United Kingdom
    Nanomedicine 4:19-29. 2008
    Superparamagnetic nanoparticles have been synthesized that could potentially be used to magnetically target therapeutics within the body...
  18. pmc Continuing Medical Education in Clinical Pharmacology and Therapeutics: report of a questionnaire survey
    J C Mucklow
    Department of Clinical Pharmacology, North Staffordshire Hospital NHS Trust, North Staffordshire Hospital, Stoke-on-Trent, ST4 6QG
    Br J Clin Pharmacol 52:9-16. 2001
    ..and industrial sources, that would guide members seeking up-to-date knowledge of Clinical Pharmacology and Therapeutics. The British Journal of Clinical Pharmacology (BJCP) should commission review articles on recent developments ..
  19. ncbi Toward a new generation of therapeutics: artificial cell targeted delivery of live cells for therapy
    Satya Prakash
    Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine, McGill University, 3775 University Street, Montreal, Quebec, H3A 2B4, Canada
    Appl Biochem Biotechnol 128:1-22. 2006
    ....
  20. pmc Teaching of clinical pharmacology and therapeutics in UK medical schools: current status in 2009
    Lelia O'Shaughnessy
    Division of Medicine, Brighton and Sussex Medical School, Brighton, East Sussex, UK
    Br J Clin Pharmacol 70:143-8. 2010
    Junior doctors feel poorly prepared by their training in Clinical Pharmacology and Therapeutics and commonly make prescribing errors...
  21. ncbi Prospects for stem cell therapeutics: myths and medicines
    George Q Daley
    Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge Massachusetts 02142, USA
    Curr Opin Genet Dev 12:607-13. 2002
    ..These cells have yielded modest and preliminary hints of functional reconstitution in animal models. Although encouraging, significant hurdles remain before the promise of stem cells will be realized in the clinic...
  22. ncbi Using synthetic miRNA mimics for diverting cell fate: a possibility of miRNA-based therapeutics?
    Lance P Ford
    Leuk Res 30:511-3. 2006
  23. ncbi Mitochondria-directed therapeutics
    Jeffrey S Armstrong
    Antioxid Redox Signal 10:575-8. 2008
    ..In the future, mitochondrial drug-targeting strategies will be expected to open up avenues for manipulating mitochondrial functions and allow for selective protection or eradication of cells for therapeutic gain in a variety of diseases...
  24. pmc Dealing with heterogeneity of treatment effects: is the literature up to the challenge?
    Nicole B Gabler
    Center for Healthcare Policy and Research, University of California, Davis, California, USA
    Trials 10:43. 2009
    ..We undertook this literature sample to track the use of HTE analyses over time, examine the appropriateness of the statistical methods used, and explore the predictors of such analyses...
  25. ncbi Systems biology and new technologies enable predictive and preventative medicine
    Leroy Hood
    Institute for Systems Biology, Seattle, WA, USA
    Science 306:640-3. 2004
    ..Such concepts are transforming current diagnostic and therapeutic approaches to medicine and, together with new technologies, will enable a predictive and preventive medicine that will lead to personalized medicine...
  26. ncbi Update on bereavement research: evidence-based guidelines for the diagnosis and treatment of complicated bereavement
    Baohui Zhang
    Department of Psychiatry, Brigham and Women s Hospital, Harvard Medical School Center for Palliative Care, Dana Farber Cancer Institute, Psycho oncology and Palliative Care Research, Boston, Massachusetts 02115, USA
    J Palliat Med 9:1188-203. 2006
    ....
  27. ncbi [Elementary structure of a study]
    L M Bachmann
    Horten Zentrum für praxisorientierte Forschung und Wissenstransfer, Universitatsspital Zurich
    Ther Umsch 64:663-5. 2007
    ..The domain defines the type of situation in which the occurrence relation is explored. The study population contains representatives of the domain whose experience is captured within the study...
  28. ncbi Benchmarking the clinical prosthetic dental literature on MEDLINE
    Kenichi Nishimura
    School of Dental Medicine, Harvard University, Boston, MA 02115, USA
    J Prosthet Dent 88:533-41. 2002
    ..With literature or outcomes continually evolving, it is difficult to know how much information is available, how fast it changes, or where it is located...
  29. ncbi Developing a platform for genomic medicine in Mexico
    Gerardo Jimenez-Sanchez
    Consortium for the Institute of Genomic Medicine of Mexico, Camino al Ajusco 130 101, Col Jardines en la Montaña, Mexico DF 14210, Mexico
    Science 300:295-6. 2003
    ..The plan includes establishment of an Institute of Genomic Medicine with strong intramural and extramural programs. This project is expected to ease the social and financial burden of health problems in Mexico...
  30. ncbi Early and periodic screening, diagnosis, and treatment examination completion rates for Oklahoma Medicaid managed care: 1995-1998
    J S Millar
    Oklahoma Foundation for Medical Quality, 5801 N. Broadway, Suite 400, Oklahoma City, OK 73118-7472, USA
    J Okla State Med Assoc 94:151-4. 2001
    ..The results also suggest the necessity for continued improvement in the provision of documented EPSDT examinations to individuals in Medicaid managed care plans in Oklahoma...
  31. ncbi Practice brief. Managing an effective query process
    Sue Bowman
    J AHIMA 79:83-8. 2008
  32. ncbi The future of nanofabrication and molecular scale devices in nanomedicine
    R A Freitas
    Zyvex Corp, Richardson, Texas, USA
    Stud Health Technol Inform 80:45-59. 2002
    ....
  33. ncbi Introduction to clinical guideline series
    James M Gill
    Del Med J 74:227-8. 2002
  34. ncbi [Placebo and superfluous actions in clinical practice]
    T S Barfod
    Vejle Sygehus, klinisk kemisk afdeling
    Ugeskr Laeger 163:3056-9. 2001
    ..The article asks for more research in the first and the last of these three components of therapy...
  35. pmc "Until the sun of science...the true Apollo of medicine has risen": collective investigation in Britain and America, 1880-1910
    Harry M Marks
    Institute of the History of Medicine, The Johns Hopkins University, Baltimore, MD 21205, USA
    Med Hist 50:147-66. 2006
  36. ncbi A conceptual framework of frailty: a review
    Walter M Bortz
    Stanford University School of Medicine, California, USA
    J Gerontol A Biol Sci Med Sci 57:M283-8. 2002
    ..As such, the state of frailty is largely separable from the process of aging and should thereby be susceptible to active intervention and reversal...
  37. ncbi A data mining approach to characterizing medical code usage patterns
    William E Spangler
    J F Donahue Graduate School of Business, Duquesne University, Pittsburgh, Pennsylvania 15282, USA
    J Med Syst 26:255-75. 2002
    ..The goal is to use this approach to understand how coding systems are used and to highlight areas for targeted improvement of the current coding..
  38. ncbi Citation of randomized evidence in support of guidelines of therapeutic and preventive interventions
    Ioannis A Giannakakis
    Clinical Trials and Evidence Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
    J Clin Epidemiol 55:545-55. 2002
    ..There is a clear increase in the use of randomized evidence by guidelines over time. However, several guidelines in major journals still cite few or no RCTs...
  39. ncbi Changes in diagnosis, treatment, and clinical improvement among patients receiving telemedicine consultations
    James P Marcin
    Department of Pediatrics, University of California Davis Health System, Sacramento, California 95817, USA
    Telemed J E Health 11:36-43. 2005
    ..47-4.83) and 11.22 (95% CI: 4.49-31.48), respectively. This study found that telemedicine consultations resulted in changes in diagnosis and treatment regimens and also are associated with clinical improvements...
  40. ncbi Biomedicine globalized and localized: western medical practices in an outpatient clinic of a Mexican hospital
    Kaja Finkler
    Department of Anthropology, University of North Carolina, CB3115 Alumni Building, Chapel Hill, NC 27514, USA
    Soc Sci Med 59:2037-51. 2004
    ..We must not assume that because the same medical nomenclature is used to make the diagnoses, these diagnoses are based on culturally neutral and uniform assessments...
  41. ncbi Multidimensional health assessment of 75- and 80-year-old men and women: a five-year prospective study
    Pia Laukkanen
    Health Center of the City of Jyväskylä, Jyvaskyla, Finland
    Aging Clin Exp Res 15:212-21. 2003
    ....
  42. ncbi The safe and effective use of propofol sedation in children undergoing diagnostic and therapeutic procedures: experience in a pediatric ICU and a review of the literature
    Derek S Wheeler
    Department of Pediatrics, Naval Medical Center, San Diego, CA, USA
    Pediatr Emerg Care 19:385-92. 2003
    ..To describe our experience using propofol sedation to facilitate elective diagnostic and therapeutic procedures, and to document the safety profile of propofol in this setting...
  43. ncbi The use of DNA microarrays to assess clinical samples: the transition from bedside to bench to bedside
    John A Copland
    Endocrinology Division, Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555, USA
    Recent Prog Horm Res 58:25-53. 2003
    ..Furthermore, genomic profiling will lead to new molecular targets for the development of drug therapeutics. Futuristically, one could envision personalized patient therapies based upon identification of specific ..
  44. ncbi The assessment and treatment of the acutely ill patient--the role of the patient simulator as a teaching tool in the undergraduate programme
    Jennifer MacDowall
    East Lancashire Hospitals NHS Trust, UK
    Med Teach 28:326-9. 2006
    ..The sessions will be incorporated into the teaching programme for all future final-year students...
  45. ncbi [Apoptosis: basic knowledge and applications]
    P Marchetti
    INSERM U459, 1, Place Verdun, 59045 Lille Cedex, France
    Gynecol Obstet Fertil 33:632-41. 2005
    ..The purpose of this article is to provide a background of relevance to clinicians on apoptosis, and the rationale for future therapeutic interventions directed toward the apoptotic machinery...
  46. ncbi Comorbidity in older adults: nosology of impairment, diseases, and conditions
    Arun Karlamangla
    UCLA Division of Geriatrics, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA 90095, USA
    J Gerontol A Biol Sci Med Sci 62:296-300. 2007
    ..As the knowledge base grows, the nosology can be updated to add new domains and refine extant ones...
  47. ncbi Effect of telemedicine on patients' diagnosis and treatment
    Ann B Bynum
    University of Arkansas for Medical Sciences, Little Rock, Arkansas 72204 1611, USA
    J Telemed Telecare 12:39-43. 2006
    ..The changes in diagnosis and management imply benefits for the rural population in Arkansas as a result of the use of telemedicine...
  48. ncbi Emerging medical technologies and emerging conceptions of health
    William E Stempsey
    Department of Philosophy, College of the Holy Cross, One College Street, Worcester, Massachusetts 01610, USA
    Theor Med Bioeth 27:227-43. 2006
    ..Technologies may aim at the prevention and treatment of disease, but they also bring about modifications of what we consider normal for the human being. Thus, new norms of health arise from technological innovation...
  49. ncbi BIRD: Bio-Image Referral Database. Design and implementation of a new web based and patient multimedia data focused system for effective medical diagnosis and therapy
    Francesco Pinciroli
    Dipartimento di Bioingegneria, Politecnico di Milano, Piazza Leonardo da Vinci 32, I 20133 Milan, Italy
    Stud Health Technol Inform 98:301-3. 2004
    ..The core server operation software has been developed in PHP Hypertext Preprocessor scripting language, which is very versatile and useful for crafting a dynamic Web environment...
  50. pmc NICE to start assessing diagnostic and treatment procedures
    Zosia Kmietowicz
    BMJ 326:412. 2003
  51. ncbi [Evolutionary quality control of diagnostics and therapy in hospitals]
    D Kohler
    Krankenhaus Kloster Grafschaft, Zentrum fur Pneumologie und Allergologie, Schmallenberg, Germany
    Pneumologie 56:199-200. 2002
  52. ncbi [Consultation on diagnostic and therapeutic decisions in Internal Medicine]
    B Barón Franco
    Rev Clin Esp 204:607. 2004
  53. ncbi [Expository models relative to prognosis in the Corpus Hippocraticum. (Prorrhetic 2, Diseases 1-3, Internal disease, Prognosis)]
    Daniela Fausti
    Stud Anc Med 31:101-17. 2005
    ....
  54. ncbi [Patients advice consultation versus diagnostic and therapeutic advice consultation. Different ways for the same efficiency]
    V Sanchis-Bayarri Bernal
    Rev Clin Esp 204:609-10. 2004
  55. ncbi [Diagnostic and treatment processes and the requirement of patient's consent in doctors' opinions]
    Andrzej Atras
    Zakład Etyki Akademii Medycznej w Lublinie, Lublin
    Przegl Lek 64:525-7. 2007
    ..The survey results allowed us to outline the level of knowledge and the degree of compliance with patient's rights related to the necessity of obtaining conscious consent to medical treatment...
  56. ncbi [In-patient treatment decisions]
    Marisa Bare
    Unitat d Epidemiologia Corporació Sanitària Parc Taulí Sabadell Barcelona Spain
    Med Clin (Barc) 122:130-3. 2004
    ..The aim of this study was to identify the extent to which treatment decisions for medical in-patients in three hospitals in Catalunya are supported by published evidence...
  57. ncbi [Guideline for conducting diagnostic and therapeutic examinations in hemodynamics]
    Jorge Ilha Guimaraes
    Arq Bras Cardiol 82:2-6. 2004
  58. ncbi [Practical guideline for the management of adverse events associated with BCG installations]
    Fernando Rodriguez
    Servicio de Urologia, Fundacion Puigvert, Barcelona, Espana
    Arch Esp Urol 61:591-6. 2008
    ..We present clearly and schematically the practice guideline we follow in our Center when the patient presents symptoms and morbidity secondary to BCG intravesical installations...
  59. ncbi Diagnosis and treatment of acromegaly complications
    A Giustina
    University of Brescia, Brescia, Italy
    J Endocrinol Invest 26:1242-7. 2003
    ..Effective management of co-morbid acromegaly complications will lead to improved morbidity and mortality in acromegaly...
  60. ncbi On teaching bedside diagnostic and therapeutic procedures to medical students: an annotated bibliography of audiovisual materials
    A A MacKinney
    University of Wisconsin Medical School, Madison
    J Gen Intern Med 9:153-7. 1994
    ..After reviewing all available videotapes, the author decided that videotapes should be the initial part of a multidimensional program for teaching procedures...
  61. ncbi Taking a closer look at physician-based coding
    Karen M Kostick
    J AHIMA 73:110-3; quiz 115-6. 2002
  62. ncbi Quality of healthcare information on the Internet: caveat emptor still rules
    Sam Karp
    iHealth and Technology Program, California HealthCare Foundation, Oakland, CA, USA
    Manag Care Q 10:3-8. 2002
    ..Constituencies concerned with healthcare and the Internet can take action to improve the quality of information online...
  63. ncbi New codes for 2002
    Susan Callaway
    McVey Associates, Novato, CA, USA
    Med Econ 79:21, 25. 2002
  64. ncbi ICD-9-CM committee proposes new codes, changes
    Sue Prophet
    J AHIMA 73:62-7; quiz 69-70. 2002
    ..This is part one in a two-part summary of proposals from the November ICD-9-CM Coordination and Maintenance Committee meeting. Part 2 will be published in the April 2002 Journal of AHIMA...
  65. pmc Extraction of semantic biomedical relations from text using conditional random fields
    Markus Bundschus
    Siemens AG, Corporate Technology, Information and Communications, Otto Hahn Ring 6, 81739 Munich, Germany
    BMC Bioinformatics 9:207. 2008
    ..In this paper we describe an approach that extracts both the existence of a relation and its type. Our work is based on Conditional Random Fields, which have been applied with much success to the task of named entity recognition...
  66. ncbi Development of the ICD-10 procedure coding system (ICD-10-PCS)
    R F Averill
    3M Health Information Systems, Wallingford, Connecticut, USA
    Top Health Inf Manage 21:54-88. 2001
    ..The final version of the ICD-10-PCS was released in the spring of 1998. The design, development and testing of ICD-10-PCS are discussed...
  67. ncbi [Doctors in the work of Thomas Mann]
    J Bättig
    Germanist und Kunsthistoriker, Oberfeld, Schwyz
    Praxis (Bern 1994) 95:22-6. 2006
  68. ncbi [The language of disease in the correspondence of Antonio Vallisneri]
    Benedino Gemelli
    Med Ges Gesch Beih 29:67-77, 261. 2007
    ....
  69. ncbi Confronting chaos
    Stephen M Soreff
    Education Intiatives, Nottingham, New Hampshire, USA
    Behav Healthc 26:16-20. 2006
  70. pmc Anti-ageing strategies: prevention or therapy? Showing ageing from within
    Suresh I S Rattan
    Department of Molecular Biology, University of Aarhus, Denmark
    EMBO Rep 6:S25-9. 2005
  71. ncbi [Toward a history and anthropology of the iatrogenic effects of the "fight" against disease]
    Marie Christine Pouchelle
    Asclepio 54:35-50. 2002
  72. ncbi Veterans Administration Acute Stroke (VASt) Study: lack of race/ethnic-based differences in utilization of stroke-related procedures or services
    Larry B Goldstein
    Durham Veterans Affairs Medical Center, Durham, NC, USA
    Stroke 34:999-1004. 2003
    ....
  73. ncbi How would Consumer Reports rate care in the intensive care unit?
    Michael Young
    Crit Care Med 33:1860-2. 2005
  74. ncbi US bioethics committee weighs in
    Jeffrey L Fox
    Nat Biotechnol 21:1417-8. 2003
  75. ncbi Transdifferentiation in developmental biology, disease, and in therapy
    Shifaan Thowfeequ
    Centre for Regenerative Medicine, Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath, United Kingdom
    Dev Dyn 236:3208-17. 2007
    ..We also examine transdifferentiation in mammals in relation to disease and the use of transdifferentiated cells in cellular therapy...
  76. ncbi WNTers in La Jolla
    Sergei Y Sokol
    Department of Molecular, Cell and Developmental Biology, Box 1020, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Development 134:3393-9. 2007
    ..Themes that dominated the meeting included the need for precise control over each step of the signal transduction mechanism and developing therapeutics for diseases caused by altered Wnt-signaling.
  77. pmc Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain
    G Olmos
    Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain
    Br J Pharmacol 108:597-603. 1993
    ..It is suggested that the down-regulation of NAIBS induced in vivo by clorgyline and pargyline, through a direct or indirect mechanism, may have functional implications...
  78. ncbi [Prevention and treatment of febrile neutropenia]
    F Montemurro
    Dipartimento di Scienze Biomediche ed Oncologia Umana, , Italy
    Tumori 83:S15-9. 1997
    ..In the first reports, outpatient treatment has proven to be effective, cost saving and well received by patients, but further studies are needed to accurately define low risk status and the optimal home antibiotic regimens...
  79. pmc Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance
    K D Bardhan
    District General Hospital, Rotherham, United Kingdom
    Yale J Biol Med 69:211-24. 1996
    ..The new class of drug, the reversible proton pump blocker (e.g., BY841) approaches this requirement...
  80. ncbi Recurrent or new injury outcomes after return to work in chronic disabling spinal disorders. Tertiary prevention efficacy of functional restoration treatment
    P Garcy
    PRIDE Research Foundation, Dallas, Texas, USA
    Spine (Phila Pa 1976) 21:952-9. 1996
    ..Literature review documents a surprising paucity of quality studies examining variables predictive of this important socioeconomic outcome variable...
  81. pmc Role of histamine in rodent antinociception
    P Malmberg Aiello
    Department of Preclinical and Clinical Pharmacology, University of Florence, Italy
    Br J Pharmacol 111:1269-79. 1994
    ..Involvement of the histaminergic system in the modulation of nociceptive stimuli is thus proposed...
  82. pmc Mechanism of action of the inhibitory effect of nifedipine on the growth of cultured aortic cells from spontaneously hypertensive and normotensive rats
    T Herembert
    CNRS URA 1482, Universite Rene Descartes, UFR des Saints Pères, Paris, France
    Br J Pharmacol 114:1703-9. 1995
    ..They also suggest the existence in aortic fibroblasts of interactions between calcium channel blockers of the dihydropyridine series and the mitogenic signalling pathways of growth factors contained in serum...
  83. ncbi A systematic overview of chemotherapy effects in gastric cancer
    K G Janunger
    Department of Surgery, University Hospital, , Sweden
    Acta Oncol 40:309-26. 2001
    ..In a number of randomised multi-centre adjuvant studies the inclusions rates are remarkably low, which reduces the scientific value of the studies...
  84. pmc A role for endogenous histamine in interleukin-8-induced neutrophil infiltration into mouse air-pouch: investigation of the modulatory action of systemic and local dexamethasone
    M Perretti
    Department of Biochemical Pharmacology, William Harvey Research Institute, Medical College of Saint Bartholomew s Hospital, London
    Br J Pharmacol 112:801-8. 1994
    ..The anti-inflammatory action of the glucocorticoids, as in some other models, appears to be LCl-dependent when these drugs are given systemically and LCl independent when the steroids are given locally...
  85. pmc The Indian Health Service approach to alcoholism among American Indians and Alaska Natives
    E R Rhoades
    Indian Health Service, Rockville, MD
    Public Health Rep 103:621-7. 1988
    ..The critical and decisive role played by the Indian communities themselves will determine whether ultimate success can be achieved...
  86. ncbi Increased nuclear ploidy, not cell proliferation, is sustained in the peroxisome proliferator-treated rat liver
    N D Lalwani
    Parke Davis Pharmaceutical Research, Warner Lambert Company, Ann Arbor, Michigan 48105, USA
    Toxicol Pathol 25:165-76. 1997
    ..The increase in DNA content was almost entirely accounted for by the overall polypoidy increase rather than by an absolute increase in cells...
  87. ncbi A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia
    E Kimby
    Department of Haematology, University Hospital, Huddinge, Sweden
    Acta Oncol 40:224-30. 2001
    ..In the future an individual risk-adapted therapy will be required. The clinical heterogeneity of the disease has pointed to the necessity of new predictors for prognosis evaluated in prospective trials...
  88. pmc Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs
    P Blier
    Department of Psychiatry, McGill University, , , Canada
    Br J Pharmacol 113:485-95. 1994
    ..Keywords: 5-HT reuptake blockade; monoamine oxidase inhibition; 5-HT autoreceptor; alpha 2-adrenoceptors; 5-HT3 receptors;[3H]-5-HT release; [3H]-noradrenaline release..
  89. ncbi Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks
    S Demirkaya
    , Ankara, Turkey
    Headache 41:171-7. 2001
    ..In view of these results, the effect of magnesium sulfate in acute migraine should be examined in large-scale studies...
  90. ncbi What, if anything, is controversial about calcium antagonists?
    F H Messerli
    Department of Internal Medicine, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA
    Am J Hypertens 9:177S-181S. 1996
    ....
  91. ncbi Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache
    K R Edwards
    Western New England Pain and Headache Center, Southwestern Vermont Medical Center, Bennington, VT 05201, USA
    Headache 41:976-80. 2001
    ..Relative to dihydroergotamine/metoclopramide, however, headache relief was not as likely to be sustained at 24 hours as with intravenous valproate...
  92. ncbi Effect of age on outcomes of tertiary rehabilitation for chronic disabling spinal disorders
    T Mayer
    Orthopedic Surgery, University of Texas Southwestern Medical Center, Dallas, USA
    Spine (Phila Pa 1976) 26:1378-84. 2001
    ..However, age does not affect additional surgery rates, subsequent injuries, or delays in settling financial disputes...
  93. ncbi Efficacy of nonprescription doses of ibuprofen for treating migraine headache. a randomized controlled trial
    J R Codispoti
    Medical Department, McNeil Consumer Healthcare, Fort Washington, PA 19034, USA
    Headache 41:665-79. 2001
    ..In addition, while not always statistically significant, ibuprofen provided a beneficial effect on associated symptoms of migraine including nausea, photophobia, phonophobia, and functional disability...
  94. ncbi The use of nonorganic signs and symptoms as a screening tool for return-to-work in patients with acute low back pain
    J M Fritz
    Department of Physical Therapy, School of Health and Rehabilitation Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Spine (Phila Pa 1976) 25:1925-31. 2000
    ..Other screening tools may prove more effective for the early identification of patients at increased risk for delay in returning to work after an episode of acute low back pain...
  95. ncbi The Maine Lumbar Spine Study, Part II. 1-year outcomes of surgical and nonsurgical management of sciatica
    S J Atlas
    Medical Practices Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Spine (Phila Pa 1976) 21:1777-86. 1996
    ..These results should be interpreted cautiously, because surgical treatment was not assigned randomly. Long-term follow-up will determine if these differences persist...
  96. ncbi A systematic overview of chemotherapy effects in Hodgkin's disease
    L Brandt
    Department of Oncology, University Hospital, Lund, Sweden
    Acta Oncol 40:185-97. 2001
    ..The relative contributions of chemotherapy and radiotherapy to the persistent effects are not well documented...
  97. pmc Enhancement of cyclic AMP accumulation mediated by 5-HT after chronic amitriptyline treatment in NG 108-15 cells
    M Shimizu
    Department of Psychiatry and Neuroscience, Kure National Hospital, Japan
    Br J Pharmacol 114:1282-8. 1995
    ..It is unlikely that this enhancement of cyclic AMP accumulation is caused by long-term antagonism of the 5-HT receptor by amitriptyline...
  98. pmc Regulation of nicotinic receptors in rat brain following quasi-irreversible nicotinic blockade by chlorisondamine and chronic treatment with nicotine
    H el Bizri
    Department of Pharmacology and Therapeutics, McGill University, Montreal, Canada
    Br J Pharmacol 113:917-25. 1994
    ..In contrast, it appears that chronic nicotine-induced up-regulation of[125I]-alpha BTX binding sites may result from receptor activation...
  99. ncbi Asian pharmaceutical researchers gathered at Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008
    M Nakata
    Department of Applied Biochemistry, Tokai University, Kanagawa, Japan
    Biosci Trends 2:135-6. 2008
    Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008 (JCMWDDT 22008) was held at The University of Tokyo, Tokyo, Japan, September 29, 2008...
  100. ncbi Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia
    G Sigurdsson
    , Reykjavik, Iceland
    Acta Cardiol 53:7-14. 1998
    ..2 mmol/l compared to 89% of the simvastatin patients at an average dose of 23 mg daily and only 13% of the fluvastatin patients achieved an LDL-cholesterol reduction of at least 40% compared to 63% of the simvastatin patients...

Research Grants85

  1. Discovery metabolite profiling of the prolyl peptidases
    Alan Saghatelian; Fiscal Year: 2009
    ..Furthermore, the application of DMP to peptidases will demonstrate the generality of this approach for the future characterization of medically relevant enzymes and signaling pathways. ..
  2. Variation in M. tuberculosis in response to host selection
    Sarah Fortune; Fiscal Year: 2009
    ..In these studies, we expect to provide fundamental insights into the mechanisms and targets of diversifying immune selection in M. tuberculosis. ..
  3. Personalized Clinical Diagnostics and Beyond: Integrated Ring Resonator Arrays
    Ryan Bailey; Fiscal Year: 2009
    ..This technology promises to broadly impact the landscape of the biomedical sciences, both meeting the clinical diagnostic challenges of today and pioneering the paradigm-shifting discoveries of tomorrow. ..
  4. Serpin Modulation of Inflammatory Vasculitis; Potential for Immunomodulatory Ther
    ALEXANDRA ROSE LUCAS; Fiscal Year: 2010
    ..therapeutic intervention with a new class of anti-inflammatory serine protease inhibitor (serpin) therapeutics. Takayasu's Disease (TKD) and Giant Cell Temporal Arteritis (GCTA) are pan-vasculitic syndromes, causing ..
  5. CFI Pathogen Inactivation Technology
    Trevor P Castor; Fiscal Year: 2010
    ..to human plasma and human plasma proteins, the developed technology will also be applicable to recombinant therapeutics, monoclonal antibodies, transgenics and vaccines...
  6. Anti-tumor properties of curcumin in oral cancers: role of thioredoxin reductase
    STEPHEN WILLIAM TUTTLE; Fiscal Year: 2010
    ..Chemical inhibitors of TxRd have yielded promising results in preclinical and clinical trials as cancer therapeutics and radiation sensitizers...
  7. A Hybrid PARP Inhibitor and Redox Catalyst for Lung Transplantation
    GARRY JOHN SOUTHAN; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a novel bifunctional small molecule, R-503, intended for the prevention of lung ischemia-reperfusion injury (LIRI) associated with orthotopic lung ..
  8. Peroxynitrite Decomposition Catalyst and Nitric Oxide Donor for Endotoxemia
    GARRY JOHN SOUTHAN; Fiscal Year: 2012
    ..To correct this free radical imbalance, Radikal Therapeutics (RTX) is developing a first- in-class small molecule drug (R-100), a bifunctional redox-based technology formed ..
  9. Vitamin D3, Interference with Androgen Signal and Inhibition of Prostate Cancer
    Bandana Chatterjee; Fiscal Year: 2013
    ..anti-proliferation signaling will define mechanisms that may be targeted to develop novel prostate cancer therapeutics. The project has high relevance to health care issues of the Veterans population...
  10. Development of a Nonpsychotropic Cannabinoid Agonist for the Treatment of Sclerod
    Robert B Zurier; Fiscal Year: 2012
    ..PUBLIC HEALTH RELEVANCE: JB Therapeutics has assembled an exceptional scientific team to study the pharmacology and mechanism of action of its novel non-..
  11. Reactive (AA)Amyloidosis
    Merrill D Benson; Fiscal Year: 2013
    ..Successful completion of these aims will offer a basis for development of specific therapeutics to treat this fatal disease...
  12. Role of Txnip in adapting fuel metabolism to nutritional state
    SIMON HUI; Fiscal Year: 2013
    ..Results of this proposed research will provide fundamental information that may lead to better prevention and/or therapeutics for diabetes and cardiovascular disease in humans.
  13. Discovery of Small Molecule MBT Domain Antagonists
    STEPHEN VERNON FRYE; Fiscal Year: 2010
    ..The chemical probes designed, synthesized and validated in this proposal will have applications in the discovery of molecular targets to treat diseases such as cancer and in the development of safe stem cell based therapeutics.
  14. Cellular &Inflammatory Pathways in Ashtma &Allergic Diseases: From IgE to Cells
    LAWRENCE BARRY SCHWARTZ; Fiscal Year: 2012
    ..Despite these progresses in our understanding of allergy pathogenesis and improved therapeutics, there remains a great deal to be learned to better control asthma and other allergic diseases...
  15. Effect of PPARy Ligands on Alcohol-Induced Alveolar Macrophage Oxidative Stress
    Samantha M Yeligar; Fiscal Year: 2013
    ..of mouse models to assess alveolar macrophage phagocytosis in vivo, b) methods to directly deliver PPAR? ligand therapeutics to the lungs of mouse models using intranasal administration, and c) skills required to develop and manage ..
  16. The Habenulo-Interpeduncular Pathway and Nicotine
    Christie D Fowler; Fiscal Year: 2013
    ..for further identification of novel drug targets with the goal of developing more efficacious smoking cessation therapeutics. With regard to career development, the mentored career training in this proposal will be equally essential to ..
  17. Regulation of ER stress-induced cell death
    Randal J Kaufman; Fiscal Year: 2013
    ..The proposed studies on protein synthesis will provide vital information that should encourage the development of novel therapeutics to treat diabetes.
  18. A Soft Topical Antiandrogenic Drug
    Wei Chu Xu; Fiscal Year: 2013
    ..We and our collaborators at Hygeia Therapeutics Inc...
  19. Investigating Mechanism of Intracellular Rotational Transport with Optical T
    Jeffrey N Anker; Fiscal Year: 2012
    ..provided by applicant): With the increased use of engineered nanoparticles in medicine (diagnostics and therapeutics), electronics, cosmetics, and textiles and the corresponding awareness of the toxicity from such nanoparticles, ..
  20. A Hybrid Katp Channel Opener to Prevent Radiocontrast-Induced Nephropathy
    Kanneganti Murthy; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a novel K+-ATP channel opener (R-801) for the prevention of radiocontrast media (CM) induced nephropathy (CIN), a devastating complication developing in >25%..
  21. Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
    Paul J Shami; Fiscal Year: 2012
    ..JSK Therapeutics (JSKT) has designed a class of diazeniumdiolate prodrugs that release NO upon interaction with glutathione in a ..
  22. Controlling Radiation Injury by TLR5 Agonists
    Andrei V Gudkov; Fiscal Year: 2012
    ..an emerging class of radiation antidotes that will allow improved understanding of their potential as human therapeutics targeting acute radiation syndrome...
  23. Oklahoma Autoimmunity Center of Excellence
    Judith A James; Fiscal Year: 2013
    ..who have research interests in the etiology and pathogenesis of autoimmune diseases and seek to identify novel therapeutics for more effective patient treatments...
  24. Alpha B crystallin as a novel therapeutic for SIRS and Sepsis
    Jonathan B Rothbard; Fiscal Year: 2011
    ..This data provides scientific foundation that Cryab can be distinguished from the large number of potential therapeutics that have not achieved their clinical milestones in this complex disease...
  25. Neuroprotection and Myelin Repair Mechanisms in Multiple Sclerosis
    Inderjit Singh; Fiscal Year: 2013
    ..Elucidation of this mechanism will permit us to design new therapeutics to promote myelin repair and limit the progression of MS in affected individuals...
  26. Regulation of microRNA-375 by cyclic-AMP in pancreatic beta-cells
    DAVID MATTHEW KELLER; Fiscal Year: 2010
    ..For this reason, the cAMP signaling pathway is currently being targeted by therapeutics for type 2 diabetes mellitus (Drucker and Nauck, 2006)...
  27. Bi-functional Therapeutics for Allergy-BFTA
    Swey Shen Chen; Fiscal Year: 2010
    ..Herein, we propose a pan-IgE therapeutics (PIT) based on recent laboratory observation in that the receptor-binding CH(2 and CH(3 linker loop (C(2-3L) of ..
  28. MODULATION OF IFN ACTION VIA NOVEL REGULATORY FACTORS
    DHAN V KALVAKOLANU; Fiscal Year: 2013
    ..These in turn will allow a better design of therapeutics to combat tumor progression and metastasis...
  29. Fatty acid related regulation of enteric infectious disease
    FREDRICK JON KULL; Fiscal Year: 2012
    ..fatty acid mediated mechanism to regulate pathogenic activity, thereby laying the groundwork for development of therapeutics that could be broadly applied to treat enteric bacterial infections causing diseases such as travelers'..
  30. Central Action of Brain-Derived Neurotrophic Factor in Male and Female Rats
    Haifei Shi; Fiscal Year: 2010
    ..of the BDNF system with the long term goal to generate data that will be useful in developing gender-specific therapeutics to treat or prevent obesity...
  31. BONE MATRIX AND BONE RESORPTION
    Paul R Odgren; Fiscal Year: 2012
    ..called osteoclasts, and every new factor we discover that affects osteoclast activity is a potential target for therapeutics. This proposal aims to investigate new genes that regulate the formation and activity of osteoclasts to better ..
  32. Hybrid Katp Channel Opener and Redox Catalyst for Lung Transplantation
    Prakash Jagtap; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a novel cytoprotective agent (R-801) for the prevention of ischemia-reperfusion injury (IRI) following lung transplantation (LTX)...
  33. Molecular Basis of E. coli Adhesins in Bladder Disorders
    Scott J Hultgren; Fiscal Year: 2013
    ..Consequently, multi-drug resistance is rising rapidly. Thus, there is a critical need for new therapeutics to better treat and prevent chronic recurrences...
  34. Identification and Analysis of Flavivirus Protease and RNA Helicase Inhibitors
    Radhakrishnan Padmanabhan; Fiscal Year: 2009
    ..One of the long term goals of this laboratory has been to develop antiviral therapeutics through understanding of key pathways in the viral life cycle using in vitro enzymatic assays that mimic those ..
  35. Molecular mechanisms of lung disease in ataxia telangiectasia
    JoAnn M Sekiguchi; Fiscal Year: 2013
    ..are to elucidate the cellular and molecular mechanisms underlying ILD in A-T patients and to identify potential therapeutics to prevent or effectively treat this potentially fatal disease phenotype...
  36. Phage Display for Improved Peptide-based Tumor Targeting and Imaging Agents
    Susan L Deutscher; Fiscal Year: 2013
    ..This work is significant and relevant to the VA mission because the peptides discovered here may translate into novel prostate, breast, and ovarian cancer diagnostics and therapeutics for our veterans.
  37. Alzheimer's Disease Therapeutic
    Trevor P Castor; Fiscal Year: 2012
    ..establish a wholly owned subsidiary Amylon Pharmaceuticals to focus on the discovery and development of novel therapeutics for Alzheimer's Disease and Cognitive Disorders with bryostatin-1 as its lead compound...
  38. Targeting CC-Chemokine Receptor 7 for the prevention of graft-versus-host disease
    JAMES M COGHILL; Fiscal Year: 2013
    ..goal is to run his own laboratory, with a focus on GVHD pathogenesis and the use of novel, small molecule therapeutics for its treatment and/or prevention...
  39. Mechanisms of Endothelin 1-Induced Sickle Cell Pathology
    Alicia Rivera; Fiscal Year: 2011
    ..block sickle erythrocyte dehydration in vivo and in vitro and as such, may represent a novel class of therapeutics for SCD...
  40. A Bifunctional Katp Channel Activator and Redox Mimetic for BPD
    Kanneganti Murthy; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Radikal Therapeutics is developing a novel small molecule therapy (R-801) for neonatal prematurity that triggers an endogenous cytoprotective defense and thereby blocks pulmonary inflammation and ..
  41. Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis
    JUSTIN RODNEY SAVAGE; Fiscal Year: 2013
    ..In Phase I, GlycoMira Therapeutics described a proprietary family of 5 kDa semi-synthetic glycosaminoglycan ethers (SAGEs), derived from sulfation ..
  42. BBP (Bone Morphogenetic Protein Binding Peptide) and Bone Healing
    SAMUEL SCOTT MURRAY; Fiscal Year: 2013
    ..relevance of this project is direct because the object is to produce materials that can be translated into therapeutics. Complex fractures, non-unions, and large bone defects due to trauma or cancer surgery that require extensive ..
  43. Autoimmunity Center of Excellence (ACE) at Stanford
    CHARLES GARRISON FATHMAN; Fiscal Year: 2013
    ..and will both test efficacy of therapy and develop tests to characterize the mechanisms of action of these therapeutics. The proposed Pilot and Feasibility Project proposes a two year research plan in Systemic Juvenile Idiopathic ..
  44. A Novel Thioredoxin Mimetic Prodrug for Prevention of Bronchopulmonary Dysplasia
    Prakash Jagtap; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a novel pharmaceutical therapy for prematurity that targets a developmental deficiency in thioredoxin (Trx), a protein that serves as a central regulator of ..
  45. Preclinical drug trial in mouse models of inflammation
    Kanneboyina Nagaraju; Fiscal Year: 2011
    ..drug screening facility in the USA that is capable of screening large numbers of drugs or other experimental therapeutics particularly for rare inflammatory muscle diseases...
  46. UV-induced and NOS-mediated Zn elevation, translation regulation and apoptosis
    Shiyong Wu; Fiscal Year: 2012
    ..UV-irradiation will lead us to a new signaling network for identification of target genes and development of therapeutics in the prevention and treatment of UV-related cancers...
  47. New therapeutics for the treatment of Acinetobactor baumannii infections.
    ALLEN BERNARD REITZ; Fiscal Year: 2013
    ....
  48. Mitochondrial and Nuclear Mechanisms of Estrogen Receptor-Mediated Cardioprotecti
    DONNA HOPE KORZICK; Fiscal Year: 2012
    ..for the treatment of acute coronary syndrome in the aging population and address the potential use of ER/PKC5 therapeutics as viable approaches to improve IT in post-menopausal women...
  49. Regulation of NFkappaB activity by the Estrogen Receptor
    Kendall W Nettles; Fiscal Year: 2012
    ..in inflammatory disease, this work also has great potential to directly impact the development of improved therapeutics. The overall goal of this project is to improve the prevention and treatment of inflammatory disease through ..
  50. Antibody-mediated Gene Therapy for the Treatment of Cancer
    TRACY RUTH DANIELS-WELLS; Fiscal Year: 2013
    ..in eliminating malignant B cells in vivo without the severe side effects that limit the efficacy of most cancer therapeutics. The antibody-avidin fusion protein that targets the TfR is a unique drug since it serves as a universal ..
  51. Intracellular Serpin Regulation of Intestinal Cell Necrosis
    GARY ARTHUR SILVERMAN; Fiscal Year: 2012
    ..Conservation of this pathway provides the rationale for eventually developing novel anti- necrosis therapeutics using this C. elegans platform. The specific aims are to 1) define the genetic basis of C...
  52. PARP inhibitor and Redox Catalyst Conjugate for Traumatic Brain Injury
    Kanneganti Murthy; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a novel bifunctional agent (R-503) that blocks two principal pathophysiolgoical pathways that contribute to traumatic brain injury (TBI)...
  53. Pilot Studies of the Effect of Aging on Mucociliary Clearance
    Lawrence E Ostrowski; Fiscal Year: 2013
    ..of the mechanisms responsible for the reduced rate of MCC in the elderly and to the development and testing of therapeutics designed to improve MCC in this population...
  54. Mechanism of Age-Related Change in Estrogen Receptor Beta Expression in Rat Brain
    JENNE MITCHELL WESTBERRY; Fiscal Year: 2012
    ..These insights could lead to development of therapeutics that result in improved cognition in the postmenopausal woman by potentially preventing changes in ER2 gene ..
  55. Aryl Hydrocarbon Receptor Modulators for the Treatment of Hepatocellular Carcinom
    Siva Kumar Kolluri; Fiscal Year: 2012
    ..all of which make the AhR a potentially attractive molecular target for development of novel cancer therapeutics. We hypothesize that certain selective AhR modulators (SAhRMs) are capable of initiating biological responses ..
  56. Intranasal CNS delivery of drugs against organophosphorous threat agents
    ARYAN MANGALAM NAMBOODIRI; Fiscal Year: 2013
    ..Non-invasive intranasal nose-to-brain delivery offers faster delivery of therapeutics to the brain...
  57. Novel CTD inhibitors with synthetic lethality to oncogenic Ras for cancer therapy
    Bingliang Fang; Fiscal Year: 2013
    ..Ras genes but not in normal isogenic cells will be valuable prototypes for developing Ras-targeted anticancer therapeutics. In searching for such agents, we screened a chemical library and identified a compound (designated oncrasin-1) ..
  58. A fully validated assay to identify activators of ERSR in human glioma cells: ide
    Maurizio Grimaldi; Fiscal Year: 2012
    ..hit compounds will have the potential to initiate a larger effort aiming to develop and test active and safe molecules as possible therapeutics to use in the battle against adult primary brain tumors of the glial lineage.
  59. Therapeutics for Drug-Resistant Bacteria: Myxopyronins
    Richard H Ebright; Fiscal Year: 2013
    ....
  60. Development of a Porcine Model of Atherosclerosis
    Christopher Rogers; Fiscal Year: 2010
    ..with an opportunity to better understand the disease and its pathogenesis and to develop and test new therapeutics and preventative strategies...
  61. Novel Regenerative Therapy for Myocardial Infarction
    Andrew R Mendelsohn; Fiscal Year: 2011
    ..The targeted Ab will reduce or eliminate potential unwanted effects to make NRG1b1-based therapeutics practical. We expect that this new regenerative therapy will help restore heart function post-MI...
  62. Role of poly (ADP-ribose) polymerase 1 (PARP-1) in experimental colitis
    Claire Larmonier; Fiscal Year: 2013
    ..Such studies are critical in guiding future development of therapeutics targeting PARP1, with proper pharmacokinetics and pharmacodynamics...
  63. Hepatic Steatosis and ER Stress-Inducible Transcription Factor CREBH
    Kezhong Zhang; Fiscal Year: 2013
    ..Understanding the stress-induced molecular mechanisms in hepatic lipid accumulation and its associated pathogenesis is a key prerequisite for the development of new diagnostics and therapeutics targeting NAFLD.
  64. Regional Biocontainment Laboratory
    Charles Bailey; Fiscal Year: 2007
    ..on the development of animal models, host-pathogen relationships, aerobiology, and testing of vaccines and therapeutics against aerosol challenge in a Good Laboratory Practices (GLP) environment...
  65. Autologous TGF-B-Modified HSC for Repair of Vasodegenerative Diabetic Retinopathy
    STEPHEN BARTELMEZ; Fiscal Year: 2009
    ..These proposed collaborative studies between BetaStem Therapeutics and Dr...
  66. Therapeutic for Intracerebral Hemorrhage
    Dale Christensen; Fiscal Year: 2009
    ..Cognosci has recently developed novel apoE-based therapeutics that cross the blood brain barrier and exert neuroprotective and anti- inflammatory activities...
  67. Delivery of biologically active nucleic acids to epidermal cells
    ROGER L contact KASPAR; Fiscal Year: 2010
    ..such as psoriasis, have well-understood molecular pathways that could be the targets of nucleic acid therapeutics. It is not hard to imagine well over 350 distinct nucleic acid drugs designed to treat specific skin diseases...
  68. Beauveriolide-Derived Cyclodepsipeptides as a New Class of Anti-Alzheimer's Drugs
    Paul Wentworth; Fiscal Year: 2010
    ..that have been shown to be orally active ACAT inhibitors that are currently being investigated as potential therapeutics for atherosclerosis...
  69. Fully Biodegradable Polymersome-encapsulated Hemoglobin as a Novel Nanoparticle-b
    PAIMAN PETER GHOROGHCHIAN; Fiscal Year: 2010
    ..augmented in vivo bioavailablity and prolonged blood circulation half-lives over liposome-based oxygen therapeutics. PCL, a well-known implantable biomaterial, forms the vesicle membrane, and facilitates complete and safe in ..
  70. Proteomic Identification of Actionable Biomarkers in Rheumatoid Arthritis
    William H Robinson; Fiscal Year: 2010
    ..Nevertheless, the advent of biological therapeutics has led to significant advances in the treatment of RA...
  71. Homing of Stem Cells in Stroke Therapeutics
    EVAN YALE contact SNYDER; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Somatic stem cells appear to have their greatest impact on stroke therapeutics not by literally replacing cells but by protecting host neural cells &circuitry from progressive damage as well as ..
  72. Patient Awareness and Consumer Education Research Cente*
    Maria E Suarez Almazor; Fiscal Year: 2010
    ..RC will be to develop a program of excellence to improve consumers'awareness of the benefits and risks of therapeutics through research, education, and dissemination, targeting consumers and their providers...
  73. MicroRNA-Based Therapeutics for Rare Cystic Kidney Diseases
    Peter Igarashi; Fiscal Year: 2010
    ..provided by applicant): The goal of this two-year proposal is to test the feasibility of microRNA-based therapeutics as a novel strategy for the treatment of rare cystic kidney diseases...
  74. Development of Small Heat Shock Proteins as Therapeutic Agents in the Eye
    JONATHAN MARK PETRASH; Fiscal Year: 2010
    ..Currently approved protein therapeutics administered in the eye have a relatively short half-life (<10 days), which necessitates repeated injections ..
  75. Human Blood-Brain Barrier Model for CNS Drug Translation
    Eric V Shusta; Fiscal Year: 2010
    ..model derived from stem cell sources amenable to high throughput assessment of central nervous system (CNS) therapeutics for their BBB permeability, a key criterion in the translation of new brain therapeutics to the clinic...
  76. Development of ex vivo Expanded Megakaryocyte Progenitors for Platelet Recovery F
    Holger Karsunky; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Cellerant Therapeutics'goal is to develop a universal off-the-shelf cellular therapeutic of megakaryocyte progenitors (MKP) for the mitigation of irradiation-induced thrombocytopenia...
  77. Basic Mechanisms of the Epilepsies Workshops
    Antonio Delgado Escueta; Fiscal Year: 2009
    ..For the first time, these Workshops demand translation of epilepsy disease mechanisms into molecular epilepsy therapeutics. The specific objectives are to: (1) Accelerate completion of the genome of common epilepsies and rare/orphan ..
  78. Volumetric Perfusion MRI of Liver Tumors to Detect Early Response to Chemotherapy
    Scott B Reeder; Fiscal Year: 2010
    ..by applicant): In the last several years, there has been a remarkable transformation in the field of cancer therapeutics, with a shift from traditional "cytotoxic" agents to targeted therapies...
  79. DEVELOPMENT OF NOVEL ANTIEPILEPTIC DRUGS
    Manoj K Patel; Fiscal Year: 2010
    ..A direct consequence of developing such a screen would be the identification of candidate therapeutics effective in therapy resistant patients...
  80. Novel Screen for Targeted CLL Therapeutics
    Dale Christensen; Fiscal Year: 2009
    ..pharmacological activation of PP2a by inhibition of SET may provide a novel approach to development of B-CLL therapeutics. Cognosci has developed novel therapeutic peptides with potent anti-inflammatory activity in vitro and in vivo...
  81. Sodium Transport Inhibitors for Hypertension and Cystic Fibrosis
    Erik Schwiebert; Fiscal Year: 2009
    ..to screen panels of molecular libraries on polarized epithelial cell models from the kidney (to find potential therapeutics to fight hypertension) and the airways (to find potential therapeutics to fight CF)...
  82. Bone Targeting Peptides for the Prevention and Treatment of Infection
    HANNE GRON; Fiscal Year: 2009
    ..delivery, due to 1) its unique mineralized structure, distinguishing it from other tissues and 2) leading bone therapeutics such as radiodrug and osteoporosis treatments often have harsh systemic effects...
  83. Structure Based Design of Humanized Monoclonal Antibodies that Recognize Bioactiv
    JONATHAN WOJCIAK; Fiscal Year: 2009
    Currently, there are over 20 therapeutic antibodies on the market. It is the fastest growing segment of therapeutics largely because humanized mAbs have excellent safety profiles...
  84. Novel therapeutic for Alcoholic Liver Disease
    Bert Oehlen; Fiscal Year: 2009
    ..several pharmacological therapies have been tried in patients with alcoholic liver disease, none of the therapeutics so far has shown consistent improvement in the course of alcoholic liver damage...
  85. Reconstitution of thrombopoiesis by angiogenic factors
    Shahin Rafii; Fiscal Year: 2009
    ..with chemotactic activity, including Stromal Derived Factor-1 (SDF-1), SDF-1 analogue (CTCE-0214, Chemokine Therapeutics), FGF-4 and FGF-20 (CG53135, CuraGen), Kit-ligand (Amgen), VEGF-A and angiopoietin-1 by rapid regeneration of ..